Fetal risk from ACE inhibitors in the first trimester: Evidence is reassuring, but risks remain from the hypertension itself

BMJ (Online)

Volumn 343, Issue 7829, 2011, Pages

  Mitchell, Allen A ^a  

^a BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

BLOOD PRESSURE REGULATION; CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; DISEASE ASSOCIATION; DRUG USE; EDITORIAL; EVIDENCE BASED MEDICINE; FEMALE; FETUS RISK; FIRST TRIMESTER PREGNANCY; HUMAN; HYPERTENSION; NEURAL TUBE DEFECT; PRIORITY JOURNAL; RISK ASSESSMENT; NOTE; PREGNANCY;

ABNORMALITIES, DRUG-INDUCED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; FEMALE; HUMANS; PREGNANCY;

EID: 84858998395     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d6667     Document Type: Editorial

References (5)

1. Li D-K, Yang C, Andrade S, Tavares V, Ferber JR. Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations: a retrospective cohort study. BMJ 2011;343:d5931.
2. Barr M Jr. Teratogen update: angiotensin-converting enzyme inhibitors. Teratology 1994;50:399-409.
3. Cooper WO, Hernandez-Diaz S, Abrogast PG, Dudley JA, Dyer S, Gideon PS, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006;354:2443-51. (Pubitemid 43855047)
4. Lennestal R, Olausson PO, Kallen B. Maternal use of antihypertensive drugs in early pregnancy and delivery outcome, notably the presence of heart defects in the infants. Eur J Clin Pharmacol 2 009;65:615-25.
5. Caton AR, Bell EM, Druschel CM, Werler MM, Lin AE, Browne ML, et al. Antihypertensive medication use during pregnancy and the risk of cardiovascular malformations. Hypertension 2009;54:63-70.